Free Newsletter
Compounds that rev up SSRI drugs
A researcher has identified a method for boosting the activity of antidepression drugs--an advance that could revolutionize the way these therapies work. Huge amounts of SSRI drugs are prescribed every year, even though they don't work about a third of the time and often take more than a month to begin having an effect.
Guillaume Lucas and a colleague, though, successfully tested their theory that the SSRI drugs could be revved up by activating a set of proteins that recognize their presence and play a key role in releasing the molecule responsible for lifting depression. They found two compounds that did just that; one from a chemical supply company and another that had been tested and abandoned in a study regarding irritable bowel syndrome. "We can expect therapeutic benefits to appear four to five times more rapidly," says Lucas.
- see this release
- read the article from Nature
Related Articles:
Suicide stats fuel debate over SSRI drugs. Report
FDA orders new warnings for antidepressants. Report
Child suicide rise tied to FDA warnings. Report
Study highlights link between Paxil and suicide. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: